Fluoroquinolones, gonorrhea, and the CDC STD treatment guidelines [2] (multiple letters)

Sexually Transmitted Diseases

Volumn 30, Issue 6, 2003, Pages 528-530

  Berman, Stuart M ^a   Moran, John S ^a,b   Wang, Susan A ^a   Workowski, Kimberly A ^a   McGee, Zell A ^c   Grewal III, N ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG APPROVAL; DRUG USE; GONORRHEA; HEALTH SURVEY; HUMAN; LETTER; MEDICAL DECISION MAKING; MENINGITIS; PRACTICE GUIDELINE; PREVALENCE; PSEUDOMEMBRANOUS COLITIS; PUBLIC HEALTH SERVICE; RISK BENEFIT ANALYSIS; SEXUALLY TRANSMITTED DISEASE; UNITED STATES;

ANTI-INFECTIVE AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CIPROFLOXACIN; DRUG RESISTANCE, MICROBIAL; GONORRHEA; HUMANS; NEISSERIA GONORRHOEAE; PRACTICE GUIDELINES; THAILAND; UNITED STATES;

EID: 0037603104     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200306000-00012     Document Type: Letter

References (0)